CLN-PXT3003-06 A Multi-center, Randomized, Double-blind, Placebo controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A

NCT03023540

A Multi-center, Randomized, Double-blind, Placebo controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A

Associated Conditions

Charcot Marie Tooth Syndrome

Principal Investigator

Sponsor

Pharnext

The main purpose of this study is to investigate how effective PXT3003 is when compared to a placebo, on the disease progression and symptoms of CMT1A. The study also aims to assess the safety and tolerability (whether side effects of a medication can be handled by patients) of PXT3003.

This study is currently enrolling.